315 related articles for article (PubMed ID: 17973316)
1. Early relapse after rituximab chemoimmunotherapy.
Kiss F; Buslig J; Szegedi I; Scholtz B; Kappelmayer J; Kiss C
Pediatr Blood Cancer; 2008 Feb; 50(2):372-5. PubMed ID: 17973316
[TBL] [Abstract][Full Text] [Related]
2. Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemia.
Jándula BM; Nomdedeu J; Marín P; Vivancos P
Bone Marrow Transplant; 2001 Jan; 27(2):225-7. PubMed ID: 11281397
[TBL] [Abstract][Full Text] [Related]
3. [Effective combination chemotherapy with rituximab for acute lymphoblastic leukemia with bone relapse after bone marrow transplantation].
Abe T; Kitajima T; Honma K; Kurasaki T; Okazuka K; Shibasaki Y; Momoi A; Kuroha T; Masuko M; Yagisawa K; Furukawa T; Toba K; Aizawa Y
Rinsho Ketsueki; 2008 Nov; 49(11):1556-61. PubMed ID: 19047788
[TBL] [Abstract][Full Text] [Related]
4. Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia.
Claviez A; Eckert C; Seeger K; Schrauder A; Schrappe M; Henze G; von Stackelberg A
Haematologica; 2006 Feb; 91(2):272-3. PubMed ID: 16461321
[TBL] [Abstract][Full Text] [Related]
5. Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects.
Gökbuget N; Hoelzer D
Ann Hematol; 2004 Apr; 83(4):201-5. PubMed ID: 14648023
[TBL] [Abstract][Full Text] [Related]
6. Three cases of renal relapse after allogeneic hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia.
Huck K; Laws HJ; Meisel R; Traeger A; Bernbeck B; Schonberger S; Stackelberg VA; Pape H; Dilloo D
Haematologica; 2006 May; 91(5 Suppl):ECR07. PubMed ID: 16709515
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
8. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
Ladetto M; Magni M; Pagliano G; De Marco F; Drandi D; Ricca I; Astolfi M; Matteucci P; Guidetti A; Mantoan B; Bodoni CL; Zanni M; Boccadoro M; Gianni AM; Tarella C
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1270-6. PubMed ID: 17162208
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation.
Gemmel C; Cremer FW; Weis M; Witzens M; Moldenhauer G; Koniczek KH; Imbach U; Ho AD; Moos M; Goldschmidt H
Ann Hematol; 2002 Feb; 81(2):119-23. PubMed ID: 11907796
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia.
Hoelzer D
Curr Opin Oncol; 2013 Nov; 25(6):701-6. PubMed ID: 24097105
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
[TBL] [Abstract][Full Text] [Related]
13. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
[TBL] [Abstract][Full Text] [Related]
14. [Tandem application of flow cytometry and polymerase chain reaction for choice targets of minimal residual disease in childhood acute lymphoblastic leukemia].
Tie LJ; Gu LJ; Jiang LM; Zhao JC; Chen J; Pan C; Dong L; Chen J; Xue HL; Tang JY; Wang YP
Zhongguo Dang Dai Er Ke Za Zhi; 2009 Apr; 11(4):246-50. PubMed ID: 19374803
[TBL] [Abstract][Full Text] [Related]
15. Molecular detection of minimal residual disease is associated with early relapse in adult acute lymphoblastic leukemia.
Specchia G; Liso A; Pannunzio A; Albano F; Mestice A; Pastore D; Liso V
Haematologica; 2004 Oct; 89(10):1271-3. PubMed ID: 15477219
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system.
Harker-Murray PD; Thomas AJ; Wagner JE; Weisdorf D; Luo X; DeFor TE; Verneris MR; Dusenbery KE; MacMillan ML; Tolar J; Baker KS; Orchard PJ
Biol Blood Marrow Transplant; 2008 Jun; 14(6):685-92. PubMed ID: 18489994
[TBL] [Abstract][Full Text] [Related]
17. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
[TBL] [Abstract][Full Text] [Related]
18. Chemoimmunotherapy in acute lymphoblastic leukemia.
Hoelzer D; Gökbuget N
Blood Rev; 2012 Jan; 26(1):25-32. PubMed ID: 21958552
[TBL] [Abstract][Full Text] [Related]
19. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.
Sebban C; Brice P; Delarue R; Haioun C; Souleau B; Mounier N; Brousse N; Feugier P; Tilly H; Solal-Céligny P; Coiffier B
J Clin Oncol; 2008 Jul; 26(21):3614-20. PubMed ID: 18559872
[TBL] [Abstract][Full Text] [Related]
20. Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation.
Corbacioglu S; Eber S; Gungor T; Hummerjohann J; Niggli F
J Pediatr Hematol Oncol; 2003 Apr; 25(4):327-9. PubMed ID: 12679650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
